Did you discuss cosentyx's affordability?

How does Cosentyx pricing compare to other IL-17 inhibitors?

Cosentyx lists at around $6,000 per month for the standard adult dose. This figure stands above the average price of Taltz but remains comparable to Skyrizi once dosing frequency is factored in. Patients often report that insurance coverage and manufacturer programs determine whether they actually pay this amount.

What assistance programs help patients afford Cosentyx?

Novartis runs the Cosentyx Connect program, which covers copays down to as low as $0 for eligible commercial insurance patients. Medicare and Medicaid recipients generally fall outside this support. When insurance does not cover the drug, cash-pay prices through specialty pharmacies can still exceed $5,000 per month.

When does Cosentyx patent protection end?

Core patents covering the secukinumab molecule itself expire in 2025 in the United States. Biosimilar versions are already in development, with several candidates advancing through clinical trials. Entry of these competitors will likely drive price pressure downward once launched.

Why are companies challenging this patent?

Multiple generic and biosimilar makers have filed IPR petitions against Cosentyx's remaining formulation and method-of-use patents. Challenges center on obviousness and anticipation of the product's dosing regimens. Success in these petitions could shorten exclusivity and accelerate biosimilar arrival.